Glenmark Pharmaceuticals Limited (GLENMARK)
Investor Presentation - Q1 FY 26-27
Investor Presentation - Q1 FY27
- Consolidated revenue Rs 40.2bn, +23.1% y-y
- India business grew 15.5%, North America core up 19.8%, Europe up 11.9%, Emerging Markets up 27.7%
- EBITDA Rs 8.05bn, margin 20.03%; PAT Rs 4.83bn, margin 11.8%
- Launched 9 new products in North America including first generic FloVent HFA with exclusivity
- Specialty products RYALTRIS and WINLEVI gaining traction globally
- Oncology and immunology pipelines progressing with multiple clinical trials ongoing
- IGI partnership advancing with promising Phase 1 data for ISB 2001 and new IND planned for ISB 2301
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GLENMARK — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GLENMARK to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Glenmark Pharmaceuticals Limited
Important.
The summary above is generated automatically from Glenmark Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.